Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocket Pharmaceuticals, Inc. (RCKT) on June 18, 2019. The filing addresses a corporate governance matter regarding the composition of the Company's Audit Committee and its compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a governance event and does not contain financial performance data.
Material Changes
On June 18, 2019, Gotham Makker, a director and member of the Audit Committee, resigned from the Audit Committee to accept a role with RTW Investments, LP, an affiliate of the Company. This resignation caused Mr. Makker to cease being "independent" under Nasdaq Listing Rule 5605(c)(2)(A). Consequently, the Audit Committee was left with only two independent directors, falling below the required minimum of three.
Guidance, Outlook, and Risks
- Regulatory Status: The Company notified Nasdaq of the deficiency on June 18, 2019, and received an official notice of non-compliance on June 19, 2019.
- Cure Period: Under Nasdaq Listing Rule 5605(c)(4)(B), the Company is granted a cure period to regain compliance, which expires at the next annual meeting of stockholders.
- Management Outlook: The Board of Directors expects to be compliant with the Audit Committee composition requirements by or before the end of the cure period.
- Continued Service: Mr. Makker will continue to serve as an independent member of the Board of Directors for purposes of Nasdaq Listing Rule 5605(b)(1).
Investor Verification Checklist
- Verify the date of the next annual meeting of stockholders to determine the exact expiration of the cure period.
- Monitor future filings for the appointment of a new independent director to the Audit Committee.
- Confirm the Company's continued compliance status with Nasdaq to avoid potential delisting risks.